Table 2.

Patient clinical characteristics according to MAPK activity status of Prog tumors

MAPK inhibitedMAPK re-activated
FeatureValueN%N%P
Age (y)Median (range)47 (31–80)59 (16–84)0.340
SexF350%427%0.299
M350%1173%
BRAF genotypeV600E467%1067%0.701
V600K/R233%533%
AJCC M stageM1a117%17%0.500
M1c583%1493%
ECOG0467%747%0.367
1233%853%
LDHNormal467%964%0.664
Elevated233%536%
RECIST SoD (mm)aMedian (range)129 (10–142)83 (23–317)1.000
Brain metastasesAbsent583%1173%0.550
Present117%427%
Best responseResponsec350%320%0.198
No responsed350%1280%
Degree of best responsebMedian−42% (−60 to −5%)−61% (−89 to −14%)0.202
PFS (wks)Median (95% CI)16.7 (10.9–22.5)30.1 (21.2–39.1)0.010
OS (wks)Median (95% CI)30.6 (0.0–88.3)89.4 (68.4–110.4)0.360
Total patients6100%15100%

Abbreviation: SoD, sum of diameters.

  • aRECIST SoD data only available for 4 patients with MAPK inhibited Progs and 14 patients with MAPK re-activated Progs.

  • bDegree of best response data only available for 4 patients with MAPK inhibited Progs and 13 patients with MAPK re-activated Progs.

  • cRECIST complete/partial response or physician assessed as response where no RECIST performed.

  • dRECIST stable/progressive disease or physician assessed as no response where no RECIST performed.